Cargando…

Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model

We established a mouse model of microenvironment-dependent human lymphoma, and assessed the therapeutic potential of bevacizumab, an antitumor agent acting on the microenvironment. NOD/Shi-scid, IL-2Rγ(null) (NOG) mice were used as recipients of primary tumor cells from a patient with diffuse large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, F, Ishida, T, Ito, A, Sato, F, Masaki, A, Takino, H, Ri, M, Kusumoto, S, Komatsu, H, Ueda, R, Inagaki, H, Iida, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346682/ https://www.ncbi.nlm.nih.gov/pubmed/22829969 http://dx.doi.org/10.1038/bcj.2012.12

Ejemplares similares

Clinical significance of tryptophan catabolism in Hodgkin lymphoma
por: Masaki, Ayako, et al.
Publicado: (2017)

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy
por: Narita, T, et al.
Publicado: (2015)

Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
por: Ri, M, et al.
Publicado: (2012)

Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals
por: Masaki, Ayako, et al.
Publicado: (2018)

Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma
por: Kinoshita, Shiori, et al.
Publicado: (2018)

Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2020)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole
por: Yoshida, Takashi, et al.
Publicado: (2019)

Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
por: Yoshida, Takashi, et al.
Publicado: (2018)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
por: Yoshida, Takashi, et al.
Publicado: (2018)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Volunteer unrelated donor cell‐derived acute myeloid leukemia with RUNX1‐RUNX1T1
por: Hagiwara, Shinya, et al.
Publicado: (2021)

Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Biomarkers for antitumor activity of bevacizumab in gastric cancer models
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2012)

A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Achromobacter Infection Is Rare in Japanese Patients with Pulmonary B-cell Lymphoma
por: Aoyama, Satsuki, et al.
Publicado: (2017)

MUM1/IRF4 Expression Is an Unfavorable Prognostic Factor in B‐Cell Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
por: Ito, Masato, et al.
Publicado: (2002)

Acute Promyelocytic Leukemia in a Patient With Chronic Continuous Type of Crohn’s Disease
por: Kinoshita, Shiori, et al.
Publicado: (2022)

Caffeine Modulates the Antitumor Activity and Toxic Side Effects of Adriamycin
por: Sadzuka, Yasuyuki, et al.
Publicado: (1993)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF
por: Yano, Hiroki, et al.
Publicado: (2008)

Antitumor effects of duvelisib on Epstein–Barr virus‐associated lymphoma cells
por: Kawada, Jun‐ichi, et al.
Publicado: (2018)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab
por: Xiao, Xuejun, et al.
Publicado: (2022)

Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
por: Kikuchi, Takaki, et al.
Publicado: (2020)

Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2018)

Potent antitumor property of Allium bakhtiaricum extracts
por: Vafaee, Kosar, et al.
Publicado: (2019)

Furan-Conjugated Tripeptides as Potent Antitumor Drugs
por: Ali, Hunain, et al.
Publicado: (2020)

Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
por: Adam, Christian, et al.
Publicado: (2007)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma
por: Cardama, Georgina A., et al.
Publicado: (2023)

Antitumor Therapy Targeting the Tumor Microenvironment
por: Gao, Yuewen, et al.
Publicado: (2023)

Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system
por: Murase, Takayuki, et al.
Publicado: (2019)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma
por: Che, Yuxuan, et al.
Publicado: (2023)

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

Discovery of Novel Quinazoline Derivatives as Potent Antitumor Agents
por: Niu, Zhenxi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ubfpjgevjvhfd0ckjil0isd5lp